Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

4 Resultados de la búsqueda.
Relevancia Evaluación Nuevo primero Antiguo primero

Esophagogastroduodenoscopy Week 38 Mepolizumab HES NCT00086658 - Esophagogastroduodenoscopy Week 38

- 15-07-17 - 1 formulario, 1 itemgroup, 2 items, 1 idioma
Itemgroup: Esophagogastroduodenoscopy
Study part: Esophagogastroduodenoscopy Week 38/ Early Withdrawal visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Esophagogastroduodenoscopy Week 16 Mepolizumab HES NCT00086658 - Esophagogastroduodenoscopy Week 16

- 12-07-17 - 1 formulario, 1 itemgroup, 3 items, 1 idioma
Itemgroup: Esophagogastroduodenoscopy
Study part: Esophagogastroduodenoscopy Week 16.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Esophagogastroduodenoscopy Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Esophagogastroduodenoscopy Day 1 Pre-Infusion

- 11-06-17 - 1 formulario, 1 itemgroup, 2 items, 1 idioma
Itemgroup: Esophagogastroduodenoscopy
Study part: Esophagogastroduodenoscopy Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

HES Related Medical Conditions Screening Visit Mepolizumab HES NCT00086658 - HES Related Medical Conditions Screening Visit

- 04-06-17 - 1 formulario, 8 itemgroups, 34 items, 1 idioma
Itemgroups: Cardiac disorders, NERVOUS SYSTEM DISORDERS, Skin diseases, GASTROINTESTINAL DISORDERS, MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS, EYE DISORDERS, RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS, medical history Hypereosinophilic Syndrome
Study part: HES Related Medical Conditions Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial